1
|
Saruuldalai E, Park J, Kang D, Shin SP, Im WR, Lee HH, Jang JJ, Park JL, Kim SY, Hwang JA, Kim YD, Lee JH, Park EJ, Lee YS, Kim IH, Lee SJ, Lee YS. A host non-coding RNA, nc886, plays a pro-viral role by promoting virus trafficking to the nucleus. Mol Ther Oncolytics 2022; 24:683-694. [PMID: 35284627 PMCID: PMC8904404 DOI: 10.1016/j.omto.2022.02.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2021] [Accepted: 02/15/2022] [Indexed: 12/01/2022] Open
Abstract
Elucidation of the interplay between viruses and host cells is crucial for taming viruses to benefit human health. Cancer therapy using adenovirus, called oncolytic virotherapy, is a promising treatment option but is not robust in all patients. In addition, inefficient replication of human adenovirus in mouse hampered the development of an in vivo model for preclinical evaluation of therapeutically engineered adenovirus. nc886 is a human non-coding RNA that suppresses Protein Kinase R (PKR), an antiviral protein. In this study, we have found that nc886 greatly promotes adenoviral gene expression and replication. Remarkably, the stimulatory effect of nc886 is not dependent on its function to inhibit PKR. Rather, nc886 facilitates the nuclear entry of adenovirus via modulating the kinesin pathway. nc886 is not conserved in mouse and, when xenogeneically expressed in mouse cells, promotes adenovirus replication. Our investigation has discovered a novel mechanism of how a host ncRNA plays a pro-adenoviral role. Given that nc886 expression is silenced in a subset of cancer cells, our study highlights that oncolytic virotherapy might be inefficient in those cells. Furthermore, our findings open future possibilities of harnessing nc886 to improve the efficacy of oncolytic adenovirus and to construct nc886-expressing transgenic mice as an animal model.
Collapse
|
2
|
Lee YS, Bao X, Lee HH, Jang JJ, Saruuldalai E, Park G, Im WR, Park JL, Kim SY, Shin S, Jeon SH, Kang S, Lee HS, Lee JS, Zhang K, Park EJ, Kim IH, Lee YS. Nc886, a Novel Suppressor of the Type I Interferon Response Upon Pathogen Intrusion. Int J Mol Sci 2021; 22:ijms22042003. [PMID: 33670458 PMCID: PMC7922379 DOI: 10.3390/ijms22042003] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2021] [Revised: 02/09/2021] [Accepted: 02/09/2021] [Indexed: 01/20/2023] Open
Abstract
Interferons (IFNs) are a crucial component in the innate immune response. Especially the IFN-β signaling operates in most cell types and plays a key role in the first line of defense upon pathogen intrusion. The induction of IFN-β should be tightly controlled, because its hyperactivation can lead to tissue damage or autoimmune diseases. Activation of the IFN-β promoter needs Interferon Regulatory Factor 3 (IRF3), together with Nuclear Factor kappa-light-chain-enhancer of activated B cells (NF-κB) and Activator Protein 1 (AP-1). Here we report that a human noncoding RNA, nc886, is a novel suppressor for the IFN-β signaling and inflammation. Upon treatment with several pathogen-associated molecular patterns and viruses, nc886 suppresses the activation of IRF3 and also inhibits NF-κB and AP-1 via inhibiting Protein Kinase R (PKR). These events lead to decreased expression of IFN-β and resultantly IFN-stimulated genes. nc886′s role might be to restrict the IFN-β signaling from hyperactivation. Since nc886 expression is regulated by epigenetic and environmental factors, nc886 might explain why innate immune responses to pathogens are variable depending on biological settings.
Collapse
Affiliation(s)
- Yeon-Su Lee
- Division of Clinical Cancer Research, Research Institute, National Cancer Center, Goyang 10408, Korea; (Y.-S.L.); (G.P.)
| | - Xiaoyong Bao
- Department of Pediatrics, University of Texas Medical Branch, Galveston, TX 77555, USA; (X.B.); (K.Z.)
| | - Hwi-Ho Lee
- Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang 10408, Korea; (H.-H.L.); (J.J.J.); (E.S.); (W.R.I.); (S.K.); (E.J.P.); (I.-H.K.)
| | - Jiyoung Joan Jang
- Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang 10408, Korea; (H.-H.L.); (J.J.J.); (E.S.); (W.R.I.); (S.K.); (E.J.P.); (I.-H.K.)
| | - Enkhjin Saruuldalai
- Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang 10408, Korea; (H.-H.L.); (J.J.J.); (E.S.); (W.R.I.); (S.K.); (E.J.P.); (I.-H.K.)
| | - Gaeul Park
- Division of Clinical Cancer Research, Research Institute, National Cancer Center, Goyang 10408, Korea; (Y.-S.L.); (G.P.)
| | - Wonkyun Ronny Im
- Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang 10408, Korea; (H.-H.L.); (J.J.J.); (E.S.); (W.R.I.); (S.K.); (E.J.P.); (I.-H.K.)
- Department of Life Science and Multidisciplinary Genome Institute, Hallym University, Chuncheon 24252, Korea; (S.S.); (S.H.J.)
| | - Jong-Lyul Park
- Personalized Genomic Medicine Research Center, KRIBB, Daejeon 34141, Korea; (J.-L.P.); (S.-Y.K.)
- Department of Functional Genomics, University of Science and Technology, Daejeon 34113, Korea
| | - Seon-Young Kim
- Personalized Genomic Medicine Research Center, KRIBB, Daejeon 34141, Korea; (J.-L.P.); (S.-Y.K.)
- Department of Functional Genomics, University of Science and Technology, Daejeon 34113, Korea
| | - Sooyong Shin
- Department of Life Science and Multidisciplinary Genome Institute, Hallym University, Chuncheon 24252, Korea; (S.S.); (S.H.J.)
| | - Sung Ho Jeon
- Department of Life Science and Multidisciplinary Genome Institute, Hallym University, Chuncheon 24252, Korea; (S.S.); (S.H.J.)
| | - Sangmin Kang
- Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang 10408, Korea; (H.-H.L.); (J.J.J.); (E.S.); (W.R.I.); (S.K.); (E.J.P.); (I.-H.K.)
| | - Hyun-Sung Lee
- Division of Thoracic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX 77030, USA;
| | - Ju-Seog Lee
- Department of Systems Biology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA;
| | - Ke Zhang
- Department of Pediatrics, University of Texas Medical Branch, Galveston, TX 77555, USA; (X.B.); (K.Z.)
| | - Eun Jung Park
- Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang 10408, Korea; (H.-H.L.); (J.J.J.); (E.S.); (W.R.I.); (S.K.); (E.J.P.); (I.-H.K.)
| | - In-Hoo Kim
- Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang 10408, Korea; (H.-H.L.); (J.J.J.); (E.S.); (W.R.I.); (S.K.); (E.J.P.); (I.-H.K.)
| | - Yong Sun Lee
- Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang 10408, Korea; (H.-H.L.); (J.J.J.); (E.S.); (W.R.I.); (S.K.); (E.J.P.); (I.-H.K.)
- Correspondence: ; Tel.: +82–31-920-2748; Fax: +82-31-920-2759
| |
Collapse
|